Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.48 |
| ▸ | MMP7 | P09237 | 2/20 | 0.48 |
| ▸ | MMP9 | P14780 | 2/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5654242 | 0.86 | MMP1 (0.56) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL14367034 | 0.85 | LMNA (0.52) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL5652276 | 0.85 | LMNA (0.52) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL5324061 | 0.85 | MMP1 (0.58) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL5654452 | 0.85 | MMP1 (0.58) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL5320400 | 0.85 | MMP1 (0.58) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL5327846 | 0.80 | MMP1 (0.50) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL14414555 | 0.79 | HTT (0.36) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL5324458 | 0.78 | MMP1 (0.55) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL5324461 | 0.78 | MMP1 (0.55) | MMP1MMP3MMP7MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | TRIMERIS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | TRIMERIS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | TRIMERIS, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | CYP3A5, CYP3A43, CCR5 | MMP1 3234/4885MMP3 1583/4885MMP7 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.